Vasopressin

DEA Class; Rx

Common Brand Names; Vasostrict, ADH

  • Gastrointestinal Agents, Other; 
  • Vasopressin-Related; 
  • Antidiuretics, Hormone Analog

Parenteral exogenous antidiuretic hormone (ADH)
Used for increasing blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines and for prevention and treatment of postoperative abdominal distention in abdominal roentgenography
Has catecholamine-sparing effect

Indicated for the treatment of central diabetes insipidus.

For the treatment of hypotension in patients with vasodilatory shock (i.e., post-cardiotomy shock, septic shock) or hemorrhagic shock due to trauma who remain hypotensive despite fluids and catecholamines.
For postoperative abdominal distention (e.g., ileus).
For use in gastrointestinal radiography.
For the treatment of variceal bleeding or nonvariceal upper GI bleeding.
For the treatment of cardiac arrest including ventricular asystole and pulseless electrical activity (PEA) during cardiopulmonary resuscitation (CPR).

Hypersensitivity; multiple dose vial (10 mL) is contraindicated in patients with known allergy or hypersensitivity to 8-L-arginine vasopressin or chlorobutanol; the 1 mL single dose vial does not contain chlorobutanol; contraindicated only in patients with a known allergy or hypersensitivity to 8-L-arginine vasopressin

Abdominal cramps

Allergic reaction

Angina

Bronchial constriction

Circumoral pallor

Diarrhea

Nausea

Pounding in the head

Sweating

Tremor

Uterine contraction

Vertigo

Reversible diabetes insipidus

With gastrointestinal (GI) bleeding, infusion should be continued for 12-24 hours after bleeding has stopped, and dosage should then be tapered over 24-48 hours

Continuous infusion should be administered via controlled infusion device

Use caution in chronic nephritis with nitrogen retention

Patients may experience reversible diabetes insipidus, manifested by development of polyuria, a dilute urine, and hypernatremia, after cessation of treatment with vasopressin; monitor serum electrolytes, fluid status and urine output after vasopressin discontinuation; some patients may require readministration of vasopressin or administration of desmopressin to correct fluid and electrolyte shifts

Pre- and postoperative patients with polyuria may occur

Use caution in patients with seizure, migraine, asthma, heart failure, vascular disease, angina pectoris, coronary thrombosis, renal disease

Use in pregnant women only when clearly needed

A decrease in cardiac index may be observed with the use of vasopressin

There are no available data on use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; animal reproduction studies not conducted

There are no data on presence of vasopressin injection in either human or animal milk, effects on breastfed infant, or on milk production

Dependent on the route of administration and indication for therapy.

Vasopressin

injection solution for dilution

  • 20 units/mL (3-mL single-dose vial; 10-mL multidose vial); further dilution required /100mL

injection solution, ready-to-use

  • 20 units/100mL (0.2 units/mL)
  • 40 units/100mL (0.4 units/mL)
  • 60 units/100mL (0.6 units/mL)

About the Author

You may also like these

0